Columnist Sam Kirton describes how daunting an IPF prognosis can be — but also how things are looking up for patients today.

IPF treatment candidate CS014 was safe and well tolerated in volunteers in a Phase 1 trial, and showed early promise for ...

A flash flood can pose unique risks for PF patients, says columnist Sam Kirton, who shares several ways to prepare for such an emergency.

Taladegib has been granted orphan drug designation in the U.S. and the European Union as a treatment for idiopathic pulmonary ...

GRI-0621, an experimental oral therapy for IPF, has so far been tolerated well in an ongoing Phase 2 clinical trial.

Because certain IPF and post-transplant medications can cause sun sensitivity, skin protection is crucial, says columnist Sam Kirton.

A Texas researcher received a $219,000 NIH grant to study the potential of a treatment for radiation-induced pulmonary fibrosis.

Clinical trials are an important part of IPF research, says columnist Sam Kirton, but we need people willing to participate in them.

Living with pulmonary fibrosis, columnist Ann Reynoso writes, means no more independent, spontaneous days with enough energy for everything.